¼¼°èÀÇ °æ±¸ °íÇü Á¦Á¦(OSD) ¼öŹÁ¦Á¶ ½ÃÀå
Oral Solid Dosage Contract Manufacturing
»óǰÄÚµå : 1791762
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 172 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,274,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,824,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ °æ±¸ °íÇü Á¦Á¦(OSD) ¼öŹÁ¦Á¶ ½ÃÀåÀº 2030³â±îÁö 609¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 417¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â °æ±¸ °íÇü Á¦Á¦(OSD) ¼öŹÁ¦Á¶ ¼¼°è ½ÃÀåÀº 2024-2030³â°£ CAGR 6.5%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 609¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ Á¤Á¦´Â CAGR 7.3%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 300¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº ÃßÁ¤ 110¾ï ´Þ·¯, Áß±¹Àº CAGR 6.2%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ °æ±¸ °íÇü Á¦Á¦(OSD) ¼öŹÁ¦Á¶ ½ÃÀåÀº 2024³â¿¡ 110¾ï ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 97¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 6.2%·Î ÃßÁ¤µË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 5.9%¿Í 5.6%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 5.1%¸¦ º¸ÀÏ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ °æ±¸ °íÇü Á¦Á¦(OSD) ¼öŹÁ¦Á¶ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

°æ±¸ °íÇü Á¦Á¦(OSD) À§Å¹»ý»êÀÌ ±ÞÁõÇÏ´Â ÀÌÀ¯´Â?

°æ±¸ °íÇü Á¦Á¦(OSD) À§Å¹»ý»ê ½ÃÀåÀº Á¦¾àȸ»çµéÀÌ ºñ¿ë È¿À²ÀûÀ̰í È¿À²ÀûÀÎ Á¦Á¶ ¼Ö·ç¼ÇÀ» ã´Â °¡¿îµ¥ °­·ÂÇÑ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ó¹æ¾à ½ÃÀå°ú ÀϹÝÀǾàǰ(OTC) ½ÃÀå ¸ðµÎ¿¡¼­ Á¤Á¦, ĸ½¶Á¦, ¼ÒÇÁÆ®Á©¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó Á¦¾à»çµéÀº °³¹ß ¹× Á¦Á¶¼öʱâ°ü(CDMO)¿¡ Á¦Á¶¸¦ À§Å¹ÇÏ´Â °ÍÀÌ Àü·«ÀûÀÎ µ¿ÇâÀÌ µÇ°í ÀÖ½À´Ï´Ù.

¶ÇÇÑ, ±ÔÁ¦ ¿ä°Ç Áõ°¡, °¡°Ý ¾Ð¹Ú, Á¦Á¦ °³¹ßÀÇ º¹À⼺À¸·Î ÀÎÇØ Á¦¾à»ç´Â Àü¹® CDMOÀÇ Àü¹®¼ºÀ» Ȱ¿ëÇϰí ÀÖ½À´Ï´Ù. ½ÉÇ÷°üÁúȯ, ´ç´¢º´, ½Å°æÁúȯ µî ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡´Â OSD ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í ºÎÃß±â¸ç À§Å¹»ý»ê ÆÄÆ®³Ê½ÊÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

±â¼ú ¹ßÀüÀº OSD ¼öŹ Á¦Á¶¸¦ ¾î¶»°Ô °­È­½Ã۰í Àִ°¡?

Á¦Á¶ ±â¼úÀÇ Çõ½ÅÀº OSD À§Å¹ »ý»êÀÇ Àü¸ÁÀ» À籸¼ºÇϰí ÀÖ½À´Ï´Ù. ¿¬¼Ó Á¦Á¶, 3D ÇÁ¸°ÆÃ, ÷´Ü ÄÚÆÃ ±â¼úÀº »ý»ê È¿À²¼º, ¾à¹°ÀÇ »ýü ÀÌ¿ë·ü, ȯÀÚÀÇ ¼øÀÀµµ¸¦ Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. °í¼Ó ¾ÐÃà ¹× °ú¸³È­ ±â¼úÀº Àϰü¼º°ú ǰÁúÀ» Çâ»ó½ÃŲ ´ë±Ô¸ð »ý»êÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù.

¶Ç ´Ù¸¥ Áß¿äÇÑ ¹ßÀüÀº Á¦Çü ÃÖÀûÈ­ ¹× ¿¹ÃøÀû ǰÁú °ü¸®¿¡ AI¿Í ¸Ó½Å·¯´×À» Ȱ¿ëÇÏ´Â °ÍÀÔ´Ï´Ù. CDMO´Â ½º¸¶Æ® Á¦Á¶ ±â¼úÀ» ÅëÇÕÇÏ¿© ½Ç½Ã°£ ¸ð´ÏÅ͸µÀ» °­È­Çϰí, Á¦Á¶ ¿À·ù¸¦ ÁÙÀ̸ç, GMP(Good Manufacturing Practice) Áؼö¸¦ º¸ÀåÇÕ´Ï´Ù. ¶ÇÇÑ, ÇÕÁ¦(FDC) Áõ°¡·Î ÀÎÇØ º¸´Ù Á¤±³ÇÑ OSD Á¦Á¶ ´É·ÂÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

Ư¼ö-°í¿ª°¡ OSD ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä°¡ ½ÃÀå Æ®·»µå¸¦ ÁÖµµ?

Ư¼öÀǾàǰ°ú °íȰ¼º ¿ø·áÀǾàǰ(HPAPI)¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ À§Å¹»ý»êÀÇ Æ®·»µå°¡ ¹Ù²î°í ÀÖ½À´Ï´Ù. CDMO´Â Á¾¾çÇÐ, ¸é¿ª¾ïÁ¦Á¦, ÁßÃ߽Űæ°è(CNS) Ä¡·á¿¡ »ç¿ëµÇ´Â °­·ÂÇÑ È­ÇÕ¹°À» Ãë±ÞÇϱâ À§ÇØ Æ¯¼ö °Ý¸® ½Ã¼³°ú ÷´Ü ¼³ºñ¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ, Á¦¾î ¹æÃâÇü ¹× ¼­¹æÇü OSD Á¦Á¦¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó CDMO´Â º¹ÀâÇÑ Á¦Çü ±â¼ú¿¡ ´ëÇÑ Àü¹® Áö½ÄÀ» È®´ëÇØ¾ß ÇÕ´Ï´Ù. ¶ÇÇÑ, °³ÀÎ ¸ÂÃãÇü ÀÇ·á Æ®·»µåµµ OSD Á¦Á¶¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖÀ¸¸ç, Á¦¾àȸ»ç´Â ƯÁ¤ ȯÀÚÀÇ ¿ä±¸¿¡ ºÎÇÕÇϴ ǥÀû ¾à¹° Àü´Þ ¼Ö·ç¼ÇÀ» ¸ð»öÇϰí ÀÖ½À´Ï´Ù.

°æ±¸ °íÇü Á¦Á¦(OSD) À§Å¹»ý»ê ½ÃÀåÀÇ ¼ºÀå ¿øµ¿·ÂÀº?

OSD À§Å¹»ý»ê ½ÃÀåÀÇ ¼ºÀåÀº ºñ¿ë È¿À²ÀûÀÎ ÀǾàǰ Á¦Á¶¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, º¹ÀâÇÑ ±ÔÁ¦, Àü¹®È­µÈ Á¦Á¦ ±â¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ¿¬¼Ó »ý»ê°ú AI ±â¹Ý ǰÁú °ü¸®·ÎÀÇ ÀüȯÀº È¿À²¼º°ú È®À强À» ´õ¿í ³ôÀ̰í ÀÖ½À´Ï´Ù.

¶ÇÇÑ, ½ÅÈï ½ÃÀåÀÇ È®´ë¿Í ¸¸¼º ÁúȯÀÇ È®»êÀº Àú·ÅÇÑ °¡°ÝÀÇ °íǰÁú OSD ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀǾàǰ Á¦Á¶¸¦ CDMO¿¡ À§Å¹ÇÏ´Â Ãß¼¼´Â ¾ÕÀ¸·Îµµ Áö¼ÓµÉ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ½ÃÀåÀÇ ²ÙÁØÇÑ ¼ºÀåÀÌ ±â´ëµË´Ï´Ù.

ºÎ¹®

Á¦Ç°(Á¤Á¦, ĸ½¶, ºÐ¸», °ú¸³Á¦, ±âŸ Á¦Ç°);±â±¸(¹æÃâ Á¦¾î ±â±¸, Áï½Ã ¹æÃ⠱ⱸ, Áö¿¬ ¹æÃ⠱ⱸ);ÃÖÁ¾»ç¿ëÀÚ(´ë±â¾÷ ÃÖÁ¾»ç¿ëÀÚ, Áß°ß/Áß¼Ò±â¾÷ ÃÖÁ¾»ç¿ëÀÚ, ±âŸ ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ¼­, ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇÕ´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM³ª ¾÷°èº° SLM Äõ¸®¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ´ë·® ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Oral Solid Dosage Contract Manufacturing Market to Reach US$60.9 Billion by 2030

The global market for Oral Solid Dosage Contract Manufacturing estimated at US$41.7 Billion in the year 2024, is expected to reach US$60.9 Billion by 2030, growing at a CAGR of 6.5% over the analysis period 2024-2030. Tablets, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$30.0 Billion by the end of the analysis period. Growth in the Capsules segment is estimated at 7.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$11.0 Billion While China is Forecast to Grow at 6.2% CAGR

The Oral Solid Dosage Contract Manufacturing market in the U.S. is estimated at US$11.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$9.7 Billion by the year 2030 trailing a CAGR of 6.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.9% and 5.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.1% CAGR.

Global Oral Solid Dosage Contract Manufacturing Market - Key Trends & Drivers Summarized

Why Is Contract Manufacturing for Oral Solid Dosage (OSD) Expanding Rapidly?

The oral solid dosage (OSD) contract manufacturing market is experiencing robust growth as pharmaceutical companies seek cost-effective and efficient production solutions. With the rising demand for tablets, capsules, and soft gels in both prescription and over-the-counter (OTC) markets, outsourcing manufacturing to contract development and manufacturing organizations (CDMOs) has become a strategic move for pharma companies.

Additionally, increasing regulatory requirements, pricing pressures, and the complexity of formulation development are prompting drug manufacturers to leverage the expertise of specialized CDMOs. The growing prevalence of chronic diseases such as cardiovascular disorders, diabetes, and neurological conditions is further fueling demand for OSD pharmaceuticals, driving contract manufacturing partnerships.

How Are Technological Advancements Enhancing OSD Contract Manufacturing?

Innovation in manufacturing technology is reshaping the OSD contract manufacturing landscape. Continuous manufacturing, 3D printing, and advanced coating techniques are improving production efficiency, drug bioavailability, and patient compliance. High-speed compression and granulation techniques are enabling large-scale production with improved consistency and quality.

Another key advancement is the use of AI and machine learning in formulation optimization and predictive quality control. CDMOs are integrating smart manufacturing technologies to enhance real-time monitoring, reduce production errors, and ensure compliance with Good Manufacturing Practices (GMP). Additionally, the rise of fixed-dose combination (FDC) drugs is driving the need for more sophisticated OSD manufacturing capabilities.

Is the Demand for Specialty and High-Potency OSD Drugs Driving Market Trends?

The increasing focus on specialty pharmaceuticals and high-potency active pharmaceutical ingredients (HPAPIs) is reshaping contract manufacturing trends. CDMOs are investing in specialized containment facilities and advanced equipment to handle potent compounds used in oncology, immunosuppressants, and central nervous system (CNS) treatments.

Additionally, the demand for controlled-release and extended-release OSD formulations is growing, requiring CDMOs to expand their expertise in complex formulation techniques. The growing trend of personalized medicine is also influencing OSD manufacturing, as pharma companies explore targeted drug delivery solutions that cater to specific patient needs.

What’s Driving the Growth of the Oral Solid Dosage Contract Manufacturing Market?

The growth in the OSD contract manufacturing market is driven by several factors, including the rising demand for cost-effective drug production, increasing regulatory complexity, and the growing need for specialized formulation expertise. The shift toward continuous manufacturing and AI-driven quality control is further enhancing efficiency and scalability.

Additionally, the expansion of emerging markets and the increasing prevalence of chronic diseases are fueling demand for affordable and high-quality OSD pharmaceuticals. The rising trend of outsourcing drug production to CDMOs is expected to continue, ensuring steady market growth in the years ahead.

SCOPE OF STUDY:

The report analyzes the Oral Solid Dosage Contract Manufacturing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Tablets, Capsules, Powders, Granules, Other Products); Mechanism (Controlled Release Mechanism, Immediate Release Mechanism, Delayed Release Mechanism); End-Use (Large Size Companies End-Use, Medium & Small Size Companies End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 36 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â